Just to temper cefa's enthusiasm. Anti-stroke drugs are notoriously difficult to get to market. Part of the reason for this is the difficulty in structuring the appropriate clinical trial. A drug can look good all the way to phase III but wither on the vine right at the end just when success appears to be in reach.
By way of example here's an extract describing what happend to Cambridge Neuroscience's Cerestat.
"Cambridge had a promising new drug, Cerestat, for the treatment of stroke and traumatic brain injury. However, the promise is as yet unfulfilled. After what appeared to be promising Phase II studies, the company entered Phase III clinical trials. There was a lot of optimism surrounding this new approach to treating stroke. However, in June the company announced that the Phase III trials had been suspended because of an unfavorable risk-to-benefit ratio. In September the trauma trial was halted as well"
PYC Price at posting:
0.0¢ Sentiment: Buy Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)